175 related articles for article (PubMed ID: 17880000)
21. Application of the random forest classification algorithm to a SELDI-TOF proteomics study in the setting of a cancer prevention trial.
Izmirlian G
Ann N Y Acad Sci; 2004 May; 1020():154-74. PubMed ID: 15208191
[TBL] [Abstract][Full Text] [Related]
22. Assessing the statistical validity of proteomics based biomarkers.
Smit S; van Breemen MJ; Hoefsloot HC; Smilde AK; Aerts JM; de Koster CG
Anal Chim Acta; 2007 Jun; 592(2):210-7. PubMed ID: 17512828
[TBL] [Abstract][Full Text] [Related]
23. Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma.
Gourin CG; Moretz WH; Weinberger PM; Xia ZS; Liu Z; Terris DJ; Adam BL
Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1125-30. PubMed ID: 18025317
[TBL] [Abstract][Full Text] [Related]
24. The application of SELDI-TOF mass spectrometry to mammalian cell culture.
Woolley JF; Al-Rubeai M
Biotechnol Adv; 2009; 27(2):177-84. PubMed ID: 19049820
[TBL] [Abstract][Full Text] [Related]
25. Construction of a multiple myeloma diagnostic model by magnetic bead-based MALDI-TOF mass spectrometry of serum and pattern recognition software.
Wang QT; Li YZ; Liang YF; Hu CJ; Zhai YH; Zhao GF; Zhang J; Li N; Ni AP; Chen WM; Xu Y
Anat Rec (Hoboken); 2009 Apr; 292(4):604-10. PubMed ID: 19301277
[TBL] [Abstract][Full Text] [Related]
26. An approach to the characterization of serum low-molecular weight proteins/peptides in liver injury using SELDI-TOF MS and factor analysis.
Liu X; Li L; Zhang G; Sheng G; Xu W
Clin Biochem; 2007 Nov; 40(16-17):1266-71. PubMed ID: 17706629
[TBL] [Abstract][Full Text] [Related]
27. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
[TBL] [Abstract][Full Text] [Related]
28. [Establish predictive model of colorectal cancer by using surface enhanced laser desorption/ionization-time of flight-mass spectrometry].
Lai YH; Xu JM; Yu XZ; Zhong YS; Wei Y; Ren L; Zhu DX; Liu YK; Niu WX; Qin XY
Zhonghua Wai Ke Za Zhi; 2008 Jul; 46(13):995-7. PubMed ID: 19035201
[TBL] [Abstract][Full Text] [Related]
29. Clinical proteomics in breast cancer: a review.
Gast MC; Schellens JH; Beijnen JH
Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
[TBL] [Abstract][Full Text] [Related]
30. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
Geng X; Wang F; Li YG; Zhu GP; Zhang WM
J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
[TBL] [Abstract][Full Text] [Related]
31. Serum protein profiles in myasthenia gravis.
Cheng C; Wu G; Yeung SC; Li R; Bella AE; Pang J; Zhong FT; Luo H; Jin Y; Pan J
Ann Thorac Surg; 2009 Oct; 88(4):1118-23. PubMed ID: 19766792
[TBL] [Abstract][Full Text] [Related]
32. Discrimination analysis of mass spectrometry proteomics for ovarian cancer detection.
Hong YJ; Wang XD; Shen D; Zeng S
Acta Pharmacol Sin; 2008 Oct; 29(10):1240-6. PubMed ID: 18817630
[TBL] [Abstract][Full Text] [Related]
33. [Use of laser capture microdissection and surface-enhanced laser desorption ionization time-of-flight mass spectrometry to screen differential proteins in lung adenocarcinoma and lung squamous carcinoma].
Tian YX; Yang SY; Nan YD; Zhang W; Zhou B; Bu LN; Huo SF; Yu JK; Zheng S
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(3):145-8. PubMed ID: 18361807
[TBL] [Abstract][Full Text] [Related]
34. Mass spectrometry is only one piece of the puzzle in clinical proteomics.
McGuire JN; Overgaard J; Pociot F
Brief Funct Genomic Proteomic; 2008 Jan; 7(1):74-83. PubMed ID: 18308835
[TBL] [Abstract][Full Text] [Related]
35. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.
Ekegren T; Hanrieder J; Bergquist J
J Mass Spectrom; 2008 May; 43(5):559-71. PubMed ID: 18416436
[TBL] [Abstract][Full Text] [Related]
36. SELDI-TOF serum proteomics and breast cancer: which perspective?
Garrisi VM; Abbate I; Quaranta M; Mangia A; Tommasi S; Paradiso A
Expert Rev Proteomics; 2008 Dec; 5(6):779-85. PubMed ID: 19086858
[TBL] [Abstract][Full Text] [Related]
37. The synergy of elemental and biomolecular mass spectrometry: new analytical strategies in life sciences.
Becker JS; Jakubowski N
Chem Soc Rev; 2009 Jul; 38(7):1969-83. PubMed ID: 19551177
[TBL] [Abstract][Full Text] [Related]
38. [Establishment of a diagnostic model of serum protein fingerprint pattern for esophageal cancer screening in high incidence area and its clinical value].
Wang SJ; Zhang LW; Yu WF; Yu JK; Zheng S; Li YS; Er LM; Wen DG; Gao JH
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):441-3. PubMed ID: 17974279
[TBL] [Abstract][Full Text] [Related]
39. Proteomics: beginning to realize its promise?
Patterson SD
Arthritis Rheum; 2004 Dec; 50(12):3741-4. PubMed ID: 15593199
[No Abstract] [Full Text] [Related]
40. Multivariate analysis approach to the plasma protein profile of patients with advanced colorectal cancer.
Ragazzi E; Pucciarelli S; Seraglia R; Molin L; Agostini M; Lise M; Traldi P; Nitti D
J Mass Spectrom; 2006 Dec; 41(12):1546-53. PubMed ID: 17117375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
